(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma...
Stats | |
---|---|
आज की मात्रा | 4.85M |
औसत मात्रा | 1.64M |
बाजार मूल्य | 210.38M |
EPS | $0 ( 2024-03-20 ) |
अगली कमाई की तारीख | ( $0 ) 2024-05-07 |
Last Dividend | $0.150 ( 2012-12-18 ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.85 |
ATR14 | $0.0510 (4.95%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-07-31 | Bradrick Brittany | Sell | 27 380 | Common Stock, $0.001 par value |
2023-07-31 | Bradrick Brittany | Sell | 86 301 | Stock Option (Right to Buy) |
2023-07-31 | Mcgahan Keith M | Sell | 195 485 | Common Stock, $0.001 par value |
2023-07-31 | Mcgahan Keith M | Sell | 386 057 | Common Stock, $0.001 par value |
2023-07-31 | Mcgahan Keith M | Sell | 778 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-27.56 |
Last 97 transactions |
Buy: 24 888 642 | Sell: 15 180 768 |
मात्रा सहसंबंध
Spectrum Pharmaceuticals सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध | |
---|---|
IRMD | 0.941 |
IDCC | 0.939 |
SLMBP | 0.939 |
DRNA | 0.933 |
PRAA | 0.924 |
MESA | 0.923 |
PIRS | 0.923 |
GALT | 0.922 |
HLIO | 0.92 |
IOAC | 0.919 |
10 सबसे अधिक नकारात्मक सहसंबंध | |
---|---|
GMII | -0.923 |
AVIR | -0.911 |
TUEM | -0.907 |
JRJC | -0.896 |
AFYA | -0.896 |
EAR | -0.887 |
GSMG | -0.885 |
DTSS | -0.883 |
ATSG | -0.881 |
GOEV | -0.88 |
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Spectrum Pharmaceuticals सहसंबंध - मुद्रा/वस्त्र
Spectrum Pharmaceuticals वित्तीय
Annual | 2022 |
राजस्व: | $10.11M |
सकल लाभ: | $8.32M (82.28 %) |
EPS: | $-0.430 |
FY | 2022 |
राजस्व: | $10.11M |
सकल लाभ: | $8.32M (82.28 %) |
EPS: | $-0.430 |
FY | 2021 |
राजस्व: | $0.00 |
सकल लाभ: | $0.00 (0.00 %) |
EPS: | $-1.020 |
FY | 2020 |
राजस्व: | $0.00 |
सकल लाभ: | $0.00 (0.00 %) |
EPS: | $-1.290 |
Financial Reports:
No articles found.
Spectrum Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.150 | 2012-12-18 |
Last Dividend | $0.150 | 2012-12-18 |
Next Dividend | $0 | N/A |
Payout Date | 2012-12-28 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.150 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0.150 | 1.02% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -1.400 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.334 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -1.193 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.71 | 0.800 | 1.449 | 1.159 | [1 - 3] |
quickRatioTTM | 2.31 | 0.800 | 1.124 | 0.899 | [0.8 - 2.5] |
cashRatioTTM | 1.347 | 1.500 | 3.63 | 5.44 | [0.2 - 2] |
debtRatioTTM | 0.275 | -1.500 | 5.42 | -8.12 | [0 - 0.6] |
interestCoverageTTM | -19.33 | 1.000 | -8.27 | -8.27 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.320 | 2.00 | -0.107 | -0.214 | [0 - 30] |
freeCashFlowPerShareTTM | -0.322 | 2.00 | -0.161 | -0.322 | [0 - 20] |
debtEquityRatioTTM | 1.105 | -1.500 | 5.58 | -8.37 | [0 - 2.5] |
grossProfitMarginTTM | 0.889 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -1.481 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -2.18 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.239 | 0.800 | -1.740 | -1.392 | [0.5 - 2] |
Total Score | -3.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -5.75 | 1.000 | -0.682 | 0 | [1 - 100] |
returnOnEquityTTM | -1.193 | 2.50 | -9.24 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.322 | 2.00 | -0.107 | -0.322 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.320 | 2.00 | -0.107 | -0.214 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.583 | 1.500 | 9.45 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -2.51 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.111 |
Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं